PHASE I Clinical Study: Safety Evaluation of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTA0-Tyr3-Octreotate for Refractory or Recurrent Metastatic Neuroblastoma Expressing Somatostatin Receptors

Condition:   Neuroblastoma Intervention:   Drug: PRRT with 177Lu-DOTATATE Sponsor:   Institut Claudius Regaud Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials